8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 22, 2021

Edesa Biotech, Inc.

(Exact Name of Registrant as Specified in its Charter)

British Columbia, Canada	001-37619	N/A
(State<br>or Other Jurisdiction<br><br><br>of<br>Incorporation)	(Commission<br><br><br>File<br>Number)	(IRS<br>Employer<br><br><br>Identification<br>No.)
100 Spy Court<br><br><br>Markham, Ontario, Canada L3R 5H6
(Address<br>of Principal Executive Offices)

(289) 800-9600

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written<br>communications pursuant to Rule 425 under the Securities Act (17<br>CFR 230.425)
¨	Soliciting<br>material pursuant to Rule 14a-12 under the Exchange Act (17 CFR<br>240.14a-12)
---	---
¨	Pre-commencement<br>communications pursuant to Rule 14d-2(b) under the Exchange Act (17<br>CFR 240.14d-2(b))
---	---
¨	Pre-commencement<br>communications pursuant to Rule 13e-4(c) under the Exchange Act (17<br>CFR 240.13e-4(c))
---	---

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common<br>Shares	EDSA	The Nasdaq Stock Market<br>LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 5.02 Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers, Compensatory Arrangements of Certain Officers.

Amendment of Stock Option and Incentive Plan

On April 22, 2021, Edesa Biotech, Inc. (the “Company”) held its 2021 annual general meeting of shareholders (the “Annual Meeting”).  At the Annual Meeting, the Company’s shareholders approved an amendment to the Company’s 2019 Equity Incentive Compensation Plan (the “2019 Plan”) to increase the number of shares available for issuance under the 2019 Plan by 1,497,000 shares.  The amendment to the Plan became effective following its approval by the Company’s shareholders.

Under the 2019 Plan, the Company is authorized to grant options, restricted shares and restricted share units (RSUs) to any of its officers, directors, employees, and consultants and those of its subsidiaries and other designated affiliates. The 2019 Plan was originally adopted by the Company’s shareholders on October 22, 2019 by written consent following approval by the Company’s Board on October 16, 2019.  The Plan is administered by the Compensation Committee of the Company’s Board of Directors, subject to certain exceptions described in the 2019 Plan.

Following the Annual Meeting, Pardeep Nijhawan, the Company’s Chief Executive Officer, was granted an option to purchase 120,000 common shares of the Company, Kathi Niffenegger, the Company’s Chief Financial Officer, was granted an option to purchase 80,000 common shares of the Company and Michael Brooks, the Company’s President, was granted an option to purchase 80,000 common shares of the Company. Each of the options has a term of ten years, vests monthly in equal proportion over a period of thirty-six months beginning on the grant date, and have an exercise price of $5.45 per share.

Item 5.07. Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, 8,081,196 common shares, or approximately 70% of the outstanding common shares entitled to vote, were represented by proxy or in person. Set forth below are the matters submitted to the shareholders at the Annual Meeting, all of which were approved:

●

the election of seven directors, nominated by the Company’s board of directors, to serve until the Company’s annual meeting of shareholders to be held in 2022 or until their successors are duly elected and qualified (“Proposal No. 1”);

●

the appointment of MNP LLP as the Company’s auditors and independent registered public accounting firm for the ensuing year (“Proposal No. 2”); and

●

the amendment to the 2019 Plan to increase the number of shares available for issuance under the 2019 Plan by 1,497,000 shares (“Proposal No. 3”).

The final voting results for each matter submitted to a vote of the Company’s shareholders are as follows:

Proposal No. 1. Election of the Company’s Directors.

Proposal to elect seven directors to the Board:

	For	Withhold	Broker Non-Votes
Lorin Johnson, PhD	6,103,053	20,686	1,957,457
Sean MacDonald	6,101,373	22,366	1,957,457
Pardeep Nijhawan, MD	6,106,121	17,618	1,957,457
Frank Oakes	5,896,041	227,698	1,957,457
Paul Pay	6,096,271	27,468	1,957,457
Carlo Sistilli, CPA, CMA	6,096,238	27,501	1,957,457
Peter van der Velden	6,090,324	33,415	1,957,457

Proposal No. 2. Appointment of Independent Registered Public Accounting Firm.

Proposal to approve the appointment of MNP LLP as the Company’s auditors and independent registered public accounting firm for the ensuing year.

For	Withhold	Broker Non-Votes
8,023,701	57,495	0

Proposal No. 3. Amendment to the 2019 Plan.

Proposal to approve amendment to the 2019 Plan to increase the number of shares available for issuance under the 2019 Plan by 1,497,000 shares .

For	Against	Broker Non-Votes
5,804,643	319,096	1,957,457

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
10.1*	Amendment No. 1 to Edesa Biotech, Inc. 2019 Equity Incentive<br>Compensation Plan.

* Management contract or compensatory plan or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Edesa<br>Biotech, Inc.
Date:<br>April 23, 2021	By:	/s/<br>Kathi Niffenegger
	Name:	Kathi<br>Niffenegger
	Title:	Chief<br>Financial Officer

edsa_ex101

Exhibit 10.1

AMENDMENT NO. 1 TO

EDESA BIOTECH, INC. 2019 EQUITY INCENTIVE COMPENSATION PLAN

This Amendment to the Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (this “Amendment”) is made and entered into effective as of March 1, 2021 (the “Effective Date”), by Edesa Biotech, Inc., a British Columbia corporation (the “Company”).

RECITALS

WHEREAS, the Company previously adopted the Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (the “Plan”);

WHEREAS, by written consent of the Company’s Board of Directors (the “Board”), dated as of the Effective Date, the Board approved an increase of the number of shares of the Company’s Common Shares reserved for issuance under the Plan by 1,497,000, which represents a number of Common Shares equal to twenty (20) percent of the Company’s issued and outstanding Common Shares less the number of Common Shares remaining available for delivery under the Plan as of the Effective Date (the “Plan Reserve Increase”);

WHEREAS, pursuant to Section 9(f) of the Plan, the Board may amend, alter, suspend, discontinue or terminate the Plan, subject to obtaining the consent of the Company’s shareholders not later than the annual meeting next following such Board action if such shareholder approval is required;

WHEREAS, the Company obtained the requisite approval of its shareholders at its 2021 Annual General Meeting;

WHEREAS, to record the adoption of the Plan Reserve Increase by the Board, the Company has caused its authorized officer to execute this Amendment to effectuate the Plan Reserve Increase.

AGREEMENT

NOW THEREFORE, the Company hereby agrees as follows:

1. Section 4(a) of the Plan is hereby amended and restated to read as follows:

“Limitation on Overall Number of Shares Available for Delivery Under Plan. Subject to adjustment as provided in Section 9(c) hereof, the total number of Shares reserved and available for delivery under the Plan after the Amendment Date (as defined below) shall be the sum of (i) 1,497,000 plus (ii) the number of Shares remaining available for delivery under the Plan as of the Amendment Date. Any Shares that are subject to Awards of Options shall be counted against this limit as one (1) Share for every one (1) Share granted. Any Shares that are subject to Awards other than Options shall be counted against this limit as one and one-half (1.5) Shares for every one (1) Share granted. Any Shares delivered under the Plan may consist, in whole or in part, of authorized and unissued shares. For purposes hereof, “Amendment Date” shall mean March 1, 2021.

2. Except as expressly modified by this Amendment, the Plan remains in full force and effect pursuant to its terms. All references to the Plan in other documentation shall be deemed to be a reference to the Plan as amended by this Amendment.

3. This Amendment shall be governed by and construed in accordance with the laws of British Columbia without giving effect to principles of conflict of laws.

[Signature Page Follows]

IN WITNESS WHEREOF, the undersigned has caused this Amendment to be duly executed effective as of the date first written above.

EDESA BIOTECH, INC.

By: /s/Kathi Niffenegger

Name: Kathi Niffenegger

Title: Chief Financial Officer